The HLA likes and dislikes of allospecific and non-MHC-restricted cytotoxic T lymphocytes. 1996

E Nössner, and C S Falk, and P Jantzer, and C Reinhardt, and A Steinle, and D J Schendel
Institute of Immunology, University of Munich, Germany.

UI MeSH Term Description Entries
D008285 Major Histocompatibility Complex The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement. Histocompatibility Complex,Complex, Histocompatibility,Complex, Major Histocompatibility,Complices, Histocompatibility,Complices, Major Histocompatibility,Histocompatibility Complex, Major,Histocompatibility Complices,Histocompatibility Complices, Major,Major Histocompatibility Complices
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015234 HLA-A Antigens Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts. Antigens, HLA-A,HLA-A,Antigens, HLA A,HLA A Antigens
D015236 HLA-C Antigens Class I human histocompatibility (HLA) antigens encoded by a small cluster of structural genes at the C locus on chromosome 6. They have significantly lower immunogenicity than the HLA-A and -B determinants and are therefore of minor importance in donor/recipient crossmatching. Their primary role is their high-risk association with certain disease manifestations (e.g., spondylarthritis, psoriasis, multiple myeloma). Antigens, HLA-C,HLA-C,Antigens, HLA C,HLA C Antigens

Related Publications

E Nössner, and C S Falk, and P Jantzer, and C Reinhardt, and A Steinle, and D J Schendel
February 1987, British journal of haematology,
E Nössner, and C S Falk, and P Jantzer, and C Reinhardt, and A Steinle, and D J Schendel
June 1996, Immunology,
E Nössner, and C S Falk, and P Jantzer, and C Reinhardt, and A Steinle, and D J Schendel
January 1987, Immunology today,
E Nössner, and C S Falk, and P Jantzer, and C Reinhardt, and A Steinle, and D J Schendel
July 1991, Immunology letters,
E Nössner, and C S Falk, and P Jantzer, and C Reinhardt, and A Steinle, and D J Schendel
January 1986, Medical oncology and tumor pharmacotherapy,
E Nössner, and C S Falk, and P Jantzer, and C Reinhardt, and A Steinle, and D J Schendel
September 1993, Clinical and experimental immunology,
E Nössner, and C S Falk, and P Jantzer, and C Reinhardt, and A Steinle, and D J Schendel
January 1986, Annual review of nutrition,
E Nössner, and C S Falk, and P Jantzer, and C Reinhardt, and A Steinle, and D J Schendel
July 1994, Behring Institute Mitteilungen,
E Nössner, and C S Falk, and P Jantzer, and C Reinhardt, and A Steinle, and D J Schendel
September 1990, Blood reviews,
E Nössner, and C S Falk, and P Jantzer, and C Reinhardt, and A Steinle, and D J Schendel
January 1988, Annals of the New York Academy of Sciences,
Copied contents to your clipboard!